The Biosimilars Guideline: Opportunity for Revision

From the desk of Henry Leng – In my post of three months ago (published May 21, 2022) I have argued that the time has come for SAHPRA to revise its guideline for the registration of biosimilars by, firstly, evaluating the need for in vivo pharmaco-toxicological...